Soluble RAGE: Therapy and biomarker in unraveling the RAGE axis in chronic disease and aging
- 1 May 2010
- journal article
- review article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 79 (10), 1379-1386
- https://doi.org/10.1016/j.bcp.2010.01.013
Abstract
No abstract availableKeywords
Funding Information
- Juvenile Diabetes Research Foundation International
- U.S. Public Health Service
This publication has 87 references indexed in Scilit:
- Renal and Retinal Effects of Enalapril and Losartan in Type 1 DiabetesNew England Journal of Medicine, 2009
- The receptor for advanced glycation endproducts (RAGE) and cardiovascular diseaseExpert Reviews in Molecular Medicine, 2009
- Alternative splicing of the murine receptor for advanced glycation end‐products (RAGE) geneThe FASEB Journal, 2009
- Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammationAnnals of Medicine, 2009
- Binding of S100 proteins to RAGE: An updateBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2008
- Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42Published by Elsevier BV ,2008
- Severity of diabetic microvascular complications is associated with a low soluble RAGE levelDiabetes & Metabolism, 2008
- Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE–/– miceJCI Insight, 2008
- The Extracellular Region of the Receptor for Advanced Glycation End Products Is Composed of Two Independent Structural UnitsBiochemistry, 2007
- RAGE and amyloid-β peptide neurotoxicity in Alzheimer's diseaseNature, 1996